Rein Therapeutics stockholders elect director Fairey, approve say-on-pay

Rein Therapeutics, Inc.

William C. Fairey elected as Class II director for three-year term expiring 2028; 7,661,847 for, 1,621,599 withheld.
Advisory vote on named executive officer compensation approved: 8,325,803 for, 146,938 against, 810,705 abstain.
Meeting held July 23, 2025, after being adjourned from June 24, 2025; no broker non-votes recorded.

item 5.07

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.